Exiqon

NEW YORK (GenomeWeb) – Danish miRNA biomarker firm Exiqon today reported its first quarter revenues were up 2 percent year over year.

Exiqon has introduced a line of MiRcury LNA microRNA mimics that have been optimized to trigger no off-target effects.
According to the company, the oligos feature segmented passenger strands that cannot enter RISC, ensuring their complete inactivity.

Assessing epigenetic silencing of a metastasis-suppressing gene in cell-free DNA provides prognostic information for non-small cell lung cancer, according to a recent study led by researchers from the University of Athens in Greece.

NEW YORK (GenomeWeb News) – Exiqon today reported a 5 percent increase year over year in its revenues for 2013, while revenues in its fourth quarter shrank 16 percent.

Søren Echwald has been named CEO at Anapa Biotech. The Danish biotech, previously called QuantiBact, is developing molecular tools to enhance the performance of natural nucleic acids in PCR and hybridization-based assays.

Syzygy Biotech has introduced rEVAlution qPCR master mix, an environmentally safe, ready-to-use hot-start qPCR mixture.

Exiqon continues to see demand for its microRNA microarray products, though its quantitative PCR assays and functional analysis products are driving its sales, according to its CEO Lars Kongsbak.

NEW YORK (GenomeWeb News) – Exiqon today reported that its third quarter revenues declined around 1 percent year over year.

A team from the University of Potsdam in Germany has combined wild-type blocking PCR using locked nucleic acids with high-resolution melting analysis to detect DNA mutations of unknown type and position in a background of up to 10,000-fold wild-type DNA.

Pacific Biosciences has released a version of the Arabidopsis thaliana genome generated using its sequencing technology.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.